Related Experiment Video
Updated: Jun 5, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Circumventing Imatinib resistance in CML: Novel Telmisartan-based cell death modulators with improved activity and
Maximilian Gebhart1, Mostafa Alilou2, Ronald Gust1
1Department of Pharmaceutical Chemistry, Institute of Pharmacy, University of Innsbruck, CCB-Centrum for Chemistry and Biomedicine, Innrain 80-82, 6020 Innsbruck, Austria.
Abstract:
Drug resistance presents a significant challenge in cancer therapy, which has led to intensive research in resistance mechanisms and new therapeutic strategies. In chronic myeloid leukemia (CML), the introduction of Imatinib, the first tyrosine kinase inhibitor (TKI), drastically changed the outcome for patients. However, complete remission still cannot be achieved in a large number of patients in the long term. Therefore, there is a great interest in the design of new drugs to target TKI-resistant cancer cells. A promising approach to enhance the efficacy of Imatinib is the simultaneous application of cell death modulators derived from the Angiotensin II type 1 receptor blocker Telmisartan. The methyl ester (3a) of 4'-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid (LEAD-acid (4)), which is the structural core of Telmisartan, has already been shown to abolish the resistance of Imatinib in TKI-insensitive CML cells at a concentration of 5 μM. As the ester was expected to be unstable in a biological environment, this study attempted to increase the stability through structural modifications. The methyl group was exchanged for longer (3b (ethyl), 3c (propyl), 3d (butyl) and branched (3e (isopropyl), 3f (tert-butyl)) alkyl chains as well as a phenyl (3g) and 4-phenoxyphenyl (3h) group. Furthermore, the esters were bioisosterically replaced with a respective substituted carboxamide (5a-h). The LEAD-amides (5a-h) showed high stability against esterases, while amidases cleaved only the carboxamides with short alkyl chains to a small extent. Esterases hydrolyzed the LEAD-alkylesters (3a-d) dependent on the chain length with τ½ = 55-82 min. Esters with branched alkyl chains were stable and introduction of the aromatic rings mentoined above increased the half-life to τ½ = 280 min and 360 min. In cell culture medium, only 3a-d degraded to 67-78 % after 72 h. However, the uptake studies showed that approximatly 80 % of the esters accumulated in the cell within the first 1-3 h of incubation. Therefore, it can be concluded that the intact LEAD-esters and LEAD-amides caused the biological effects. The compounds were non-cytotoxic and efficiently sensitized KD225 (K562-resistant) CML cells to Imatinib at a half-maximal sensitizing concentration (SC50) of 1.5-2.9 μM (ester derivatives) and 1.3-11.2 μM (amide derivatives).
Insights
New drug derivatives based on Telmisartan effectively resensitize Imatinib-resistant chronic myeloid leukemia (CML) cells. These compounds enhance tyrosine kinase inhibitor (TKI) therapy efficacy by overcoming drug resistance, offering a promising strategy for CML treatment.
Area of Science:
- Medicinal Chemistry
- Oncology
- Pharmacology
Background:
- Drug resistance is a major hurdle in cancer therapy, particularly in chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) like Imatinib.
- While Imatinib has revolutionized CML treatment, a significant number of patients do not achieve long-term complete remission due to resistance.
- Developing novel therapeutic strategies to target TKI-resistant CML cells is crucial for improving patient outcomes.
Purpose of the Study:
- To synthesize and evaluate novel derivatives of the Telmisartan core structure (LEAD) to enhance Imatinib efficacy against TKI-resistant CML cells.
- To improve the metabolic stability of previously identified LEAD-acid (4) methyl ester (3a) through structural modifications.
- To assess the sensitizing potential of these new LEAD derivatives on Imatinib-resistant CML cells.
Main Methods:
- Synthesis of various LEAD-esters (3a-h) with modified alkyl chains and aromatic groups, and bioisosteric LEAD-amides (5a-h).
- Assessment of hydrolytic stability against esterases and amidases in vitro.
- Evaluation of the sensitizing effect of LEAD derivatives on Imatinib-resistant KD225 (K562-resistant) CML cells using half-maximal sensitizing concentration (SC50) assays.
Main Results:
- LEAD-amides (5a-h) exhibited high stability against esterases, with minimal cleavage by amidases for short alkyl chains.
- LEAD-alkylesters (3a-d) were hydrolyzed by esterases (t½ = 55-82 min), while branched and aromatic esters showed increased stability (t½ up to 360 min).
- LEAD derivatives (esters and amides) were non-cytotoxic and effectively sensitized Imatinib-resistant CML cells, with SC50 values ranging from 1.3-11.2 μM.
Conclusions:
- Structural modifications significantly enhanced the stability of LEAD derivatives, with aromatic substitutions providing the greatest stability.
- Intact LEAD-esters and LEAD-amides are responsible for the observed biological effects, accumulating effectively within cells.
- These novel LEAD derivatives represent a promising strategy to overcome Imatinib resistance in CML by sensitizing resistant cells to TKI therapy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Treatment Resistant Cancers
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

